Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$32.18 - $46.57 $210,779 - $305,033
6,550 Added 11.57%
63,160 $2.84 Million
Q3 2023

Nov 13, 2023

BUY
$44.2 - $50.2 $22,100 - $25,100
500 Added 0.89%
56,610 $2.58 Million
Q2 2023

Aug 14, 2023

BUY
$31.86 - $67.26 $50,976 - $107,616
1,600 Added 2.94%
56,110 $2.43 Million
Q1 2023

May 15, 2023

BUY
$45.44 - $74.26 $99,968 - $163,372
2,200 Added 4.21%
54,510 $3.58 Million
Q4 2022

Feb 13, 2023

SELL
$41.39 - $81.0 $387,162 - $757,674
-9,354 Reduced 15.17%
52,310 $2.35 Million
Q3 2022

Nov 14, 2022

SELL
$72.36 - $113.1 $55,717 - $87,087
-770 Reduced 1.23%
61,664 $4.46 Million
Q2 2022

Aug 12, 2022

SELL
$87.2 - $114.05 $304,764 - $398,604
-3,495 Reduced 5.3%
62,434 $6.7 Million
Q1 2022

May 16, 2022

SELL
$94.19 - $124.49 $2.47 Million - $3.26 Million
-26,178 Reduced 28.42%
65,929 $7.31 Million
Q4 2021

Feb 11, 2022

BUY
$119.57 - $139.07 $5.15 Million - $5.99 Million
43,084 Added 87.89%
92,107 $11.8 Million
Q3 2021

Nov 12, 2021

SELL
$109.17 - $142.35 $3.03 Million - $3.96 Million
-27,794 Reduced 36.18%
49,023 $6.52 Million
Q2 2021

Aug 13, 2021

BUY
$100.34 - $115.69 $476,414 - $549,296
4,748 Added 6.59%
76,817 $8.31 Million
Q1 2021

May 12, 2021

BUY
$101.51 - $125.27 $294,379 - $363,283
2,900 Added 4.19%
72,069 $7.59 Million
Q4 2020

Feb 12, 2021

BUY
$85.88 - $105.36 $47,577 - $58,369
554 Added 0.81%
69,169 $7.2 Million
Q3 2020

Nov 12, 2020

SELL
$72.74 - $92.5 $4.74 Million - $6.03 Million
-65,191 Reduced 48.72%
68,615 $5.88 Million
Q2 2020

Aug 12, 2020

BUY
$48.02 - $79.04 $52,341 - $86,153
1,090 Added 0.82%
133,806 $9.81 Million
Q1 2020

May 11, 2020

BUY
$36.95 - $62.95 $374,266 - $637,620
10,129 Added 8.26%
132,716 $6.89 Million
Q4 2019

Feb 14, 2020

BUY
$47.06 - $56.64 $5.77 Million - $6.94 Million
122,587 New
122,587 $6.9 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $10.7B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.